The molecular immunohematology assay evaluates blood compatibility between donors and patients to help prevent mismatches that can cause life-threatening reactions.
The random access system offers a diversified immunoassay menu for allergy, autoimmunity, and biotherapy monitoring.
To date, the genetic analysis is the largest genome-wide association study to focus on the eye condition.
Roche will initiate blood center testing for Zika virus under an FDA investigational new drug study protocol.
A 2015 Health Trends study conducted by Quest Diagnostics found that diabetes diagnoses surged during 2014 in states that expanded Medicaid under the Patient Protection and Affordable Care Act
The first WHO Global Report on Diabetes underscores the enormous scale of the diabetes problem, and also the potential to reverse current trends.
The number of people living with diabetes and its prevalence are growing in all regions of the world.
According to the company, overly expansive patent eligibility criteria have put into jeopardy the patentability of existing and future diagnostic method patent claims.
Researchers performed a retrospective medical records review of Medicare-eligible patients at average risk for colorectal cancer who were not previously compliant with recommended guidelines for screening.
In collaboration with the New York University College of Dentistry, Rheonix will pursue development of a fully automated screening assay that will simultaneously detect and confirm the presence of Zika virus.
BlueCross BlueShield of Florida and Health Care Services Corp have independently determined that the VeriStrat test from Biodesix is a medically necessary benefit.
Rising diabetes rates are raising concern on a global scale.
Managing test utilization is revealing opportunities for improved laboratory performance and better patient care.
The automated, multiplex DNA assay simultaneously identifies Staphylococcus aureus and other Staphylococcus species directly from positive blood cultures.
The updated system enables the exchange and management of key healthcare images, data, and reports.
The first blood-based screening test for colorectal cancer will be made available in the United States under a joint commercialization agreement with Polymedco.
Urinalysis instruments offer expanding feature sets designed to meet diverse testing requirements.
A Web-based digital pathology service offers rapid, expert review without the time delays and risks associated with shipping glass slides.
The combined screening and confirmatory test is designed especially for use in settings with limited resources.
The company’s new instrument is being designed with extensive input from laboratory customers.